ALEC - Alector, Inc.

2.16
0.110   5.093%

Share volume: 437,289
Last Updated: 05-12-2026
Pharmaceutical Products/Biological Products, Except Diagnostic Substances: 0.21%

PREVIOUS CLOSE
CHG
CHG%
$2.05
0.11
0.05%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
35%
Profitability 35%
Dept financing 41%
Liquidity 50%
Performance 30%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
2.86%
1 Month
-7.30%
3 Months
15.51%
6 Months
80.00%
1 Year
94.59%
2 Year
-59.93%
Key data
Stock price
$2.16
P/E Ratio 
0.00
DAY RANGE
$2.03 - $2.20
EPS 
-$1.19
52 WEEK RANGE
$1.01 - $3.40
52 WEEK CHANGE
$101.87
MARKET CAP 
237.280 M
YIELD 
N/A
SHARES OUTSTANDING 
111.025 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
05-07-2025
BETA 
2.04
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$443,303
AVERAGE 30 VOLUME 
$471,059
Company detail
CEO: Arnon Rosenthal
Region: US
Website: alector.com
Employees: 270
IPO year: 2019
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Biological Products, Except Diagnostic Substances
Sector: Manufacturing

Alector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, a humanized recombinant monoclonal antibody, which is in Phase III clinical trial for the. treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases.

Recent news